Kornimate/medical-research-clean huggingface dataset:
obesity alters lung mechanics in robotic surgery

Conditions: Obesity; Surgery; Anesthesia

Summary: intraoperative lung protective ventilation strategies using standardized tidal volumes based on predicted body weight have proven beneficial, but attempts to standardize positive end expiratory pressure (peep) settings have not robustly accounted for body habitus or dynamic surgical conditions. laparoscopic abdominal surgery in trendelenburg (head-down) is an increasingly common surgical modality that presents a unique physiological challenge to the pulmonary system. in order to delineate the impact of body habitus, pneumoperitoneum, and surgical positioning on intraoperative pulmonary mechanics we conducted an observational study of patients undergoing robotic assisted laparoscopic abdominal surgery in trendelenburg position. using esophageal manometry, we partitioned the mechanical properties of the respiratory system into its lung and chest wall components and evaluated the effects of pneumoperitoneum, surgical position, and body mass index (bmi) on transpulmonary pressures, airway and transpulmonary driving pressures, and lung elastance. we hypothesized that increasing bmi would be associated with evidence of increasing atelectasis, increased driving pressures, and elevated lung elastance and that these changes would be exacerbated by pneumoperitoneum and trendelenburg positioning.


Eligibility criteria:
inclusion criteria: * inclusion criteria were presentation for robotic assisted laparoscopic abdominal surgery in the supine position, age ≥ 18 years, and ability to provide informed consent exclusion criteria: * exclusion criteria included intrinsic lung disease, ≥ 20 pack year smoking history, reactive airways disease, home oxygen requirement, inability to provide informed consent, emergent surgery, or esophageal pathology (i.e., strictures, varices, history of esophageal dilatation or surgery).
using intraoperative sensing technology to evaluate revision total knee arthroplasty

Conditions: Knee Osteoarthritis

Summary: this study will attempt to draw relationships between the soft-tissue related complications contributing to early tka revision and the loading and positional patterns from intraoperative tibial trial sensors. the data from the sensors may enable the surgeon to address such soft-tissue abnormalities that may otherwise be unknown during traditional total knee revision procedures. the utilization of sensors should in theory, help diagnose the potential causes attributing to soft-tissue imbalance and may lead to a decreased need for an all component revision. furthermore, the economic implications from converting a total revision to a partial revision could have a profound effect to the patient and healthcare provider such as decreased rehabilitation regimes and opportunity for cost savings. eligible revision patients who agree to participate will be followed for a period of 12 months following the revision procedure. patient reported outcomes measures (prom) such as the 2011 knee society score (kss) and the veterans rand 12-item health survey (vr-12) will be collected at baseline (pre-operatively) and at 6 weeks, 6 months and 12 months post-procedure. all outcomes will be scored to observe changes from baseline at 12-months. cost-analyses of sensor-assisted revision tka will be performed to include or costs, facility and physician fees, as well as payments to post-acute collaborators such as snfs, rehab hospitals, pt and home care providers. a quantitative analysis of commercial payer claims / usage data (e.g., cms medpar data) will be used to examine costs associated with traditional revision tka procedures.


Eligibility criteria:
inclusion criteria: * patients undergoing revision unilateral total knee arthroplasty within the first 5-years of the index procedure * include male and female subjects * include subjects 18 years and older * patients should present with idiopathic pain and/or instability/stiffness attributed to aseptic loosening, polyethylene wear or malrotation * patients able to understand study intent, and agree to study participation * patients must be previously implanted with the following cruciate-retaining (cr) or posterior-substituting (ps) total knee systems: stryker triathlon, zimmer-biomet vanguard or nexgen or smith and nephew legion or journey ii. exclusion criteria: * no prior revision surgery on operative side * ligament insufficiencies, prior surgeries such as pcl reconstructions, posterolateral reconstructions, osteotomies, tibia plateau fractures * culture positive aspiration indicating infection of the joint * asa class \> iii * history of drug or alcohol abuse

Keywords: revision tka instability stiffness aseptic loosening polyethylene wear malrotation soft tissue imbalance
resveratrol-enriched grape extract (stilvid) in primary and secondary prevention of cardiovascular disease

Conditions: Cardiovascular Diseases

Summary: resveratrol can exhibit benefits against cardiovascular diseases (cvds) although the cardioprotective role of resveratrol as part of the human diet is not yet clear. the aim of this trial is to evaluate the safety and efficacy of a resveratrol-enriched grape extract (stilvid) in 150 patients from both primary and secondary cardiovascular prevention. all the patients are gold-standard medicated (statins and others). a number of cardiovascular risk and safety markers will be evaluated after consuming 1 cap/day for 6 months and 2 caps/day for 6 additional months (total 12 months).


Eligibility criteria:
inclusion criteria: for primary prevention: * lack of known cardiovascular disease (coronary acute syndrome, stable ischemic cardiopathy, peripheric arteriopathy and cerebrovascular diseases). * age between 18 and 80 years. * the above criteria and diabetes mellitus or at least two of the following risk factors: 1. active smoking (10 cigarettes or more per day). 2. arterial hypertension (\>= 140/90 mmhg). 3. hypercholesterolemia (ldl-cholesterol \>130 mg/dl and/or hdl-cholesterol \< 45 mg/dl in women and 50 mg/dl in men). 4. obesity (bmi \> 30 kg/m2) for secondary prevention: * stable patients who coronary syndrome, cerebrovascular accident or peripheric arteriopathy event occurred at least 6 months or more before the recruitment in the study. in addition: 1. age between 18 and 80 years. 2. ejection fraction of left ventricle \>=45%. 3. functional status i or ii according to the new york heart association. 4. clinic stability in the recruitment (no symptoms of thoracic pain during the last month). 5. lack of residual lesions without vascularization in those patients with catheterism. exclusion criteria: for primary and secondary prevention: * patients who do not satisfy inclusion criteria and: 1. known allergy to grapes 2. pregnancy or lactation 3. intake of nutraceuticals

Keywords: primary prevention secondary prevention resveratrol grape cardiovascular nutraceutical food complement
muscle fatigue in patients with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: it is stated that 85% of patients with multiple sclerosis (ms) complain of gait disorders and 35-90% of them have fatigue. many factors play a role in the fatigue mechanism in ms patients. fatigue can increase the symptoms that already exist in ms patients. it is thought that fatigue caused a decrease in muscle strength, making walking worse. there are not enough studies investigating whether fatigue affects gait parameters in ms patients. the aim of this study is to examine the effects of muscle fatigue on muscle strength, joint position sensation, and gait in ms patients.

patients with ms between 0-5,5 score according to the extended disability status scale (edss) and healthy individuals of similar age and sex to patients will be included in the study. the muscle strength, joint position sensation, gait, and fatigue will be evaluated once. the investigators will use descriptive statistics and t-tests to compare demographic characteristics between groups and for the categorical variables chi-square. effect of the group (ms patients or healthy controls), condition (single task and dual-task conditions), and group × condition interaction will be compared using two-way repeated-measures anova.

Eligibility criteria:
inclusion criteria: * participants who 18-65 years of age * ms patients who are ambulatory (expanded disability status scale score ≤ 5,5 ) in a stable phase of the disease, without relapses in the last 3 month exclusion criteria: * participants who have orthopedic, vision, hearing, or perception problems

Keywords: multiple sclerosis gait sensation fatigue
near infrared spectroscopy (nirs) for heart failure assessment.

Conditions: Cardiac Failure

Summary: it is routine practice for a cardiologist to perform a battery of tests to assess the degree of heart failure. the purpose of this study is to establish a non-invasive method to reliably predict cardiac output state in real-time in children and adolescents with heart failure in an outpatient setting. this study will rely on the use of near infrared spectroscopy monitors to measure cardiac output in the outpatient setting.

near-infrared spectroscopy (nirs) technology, such as that used in pulse oximetry, has been used in medicine for decades. several characteristics contribute to its widespread use, including its noninvasive nature, reliability and safety. the somanetics' invos® system harnesses this power to safely and reliably "see inside" the brain and body. nirs devices measure the venous weighted oxy-hemoglobin saturation (color of blue blood) in a field of tissue, rather than in arteries, and thus the rso2 parameter provides a window into regional oxygen supply-demand relationships. monitoring rso2 at two distinct sites (cerebral and somatic) has become common practice at our institution for all infants and children in the intensive care unit and provides valuable feedback about potentially deleterious trends in regional tissue oxygenation that cannot easily be obtained by other modalities in such patients.

Eligibility criteria:
inclusion criteria: * patient in phoenix children's hospital heart failure clinic exclusion criteria: * n/a

Keywords: nirs near infrared spectroscopy heart failure cardiac output outpatient pediatric
tb and sarcoidosis granuloma

Conditions: Tuberculosis; Sarcoidosis

Summary: tuberculosis (tb) and sarcoidosis are both granulomatous diseases. here we compared the immunological micro-environments of granulomas from tb and sarcoidosis patients using in situ sequencing (iss) transcriptomic analysis and multiplexed immunolabelling of tissue sections.

tuberculosis (tb) and sarcoidosis are diseases that are characterized by the formation of inflammatory structures called granulomas. tb is caused by infection with the bacteria mycobacterium tuberculosis while sarcoidosis is a an inflammatory disease of unknown ethiology. we hypothesize that the localization of immune molecules in granulomas determines the the course of tb and sarcoidosis using in situ sequencing, a spatial transcriptomic technology and immunolabelling in biopsies from patients. in the project, we aim to answer the following questions: 1. how does the immune landscape differ in different tb granulomas (with/without necrosis, different histology)? 2. how does the immune landscape differ in acute (lofgren's syndrome) and chronic (non-lofgren's syndrome) sarcoidosis samples? 3. how does the immune landscape differ in histologically similar granulomas from tb and sarcoidosis patients? we will use in situ sequencing that can identify the exact location of 65 specific immune markers in the lung at the same time, thereby correlating defined immune landscapes with the histology, bacterial content and disease type.

Eligibility criteria:
inclusion criteria: specimen were taken from patients with a confirmed diagnosis of tb based on granulomatous inflammation based on histopathological confirmation together with additional parameters such as, clinical symptoms, radiological and laboratory parameters (microscopy detection of acid-fast bacilli in sputum, m. tuberculosis culture, chest radiography, and mtb/rif genexpert analysis) were included. sarcoidosis and tb biopsies were selected by a clinical patholologist that evaluated the ocurrence of the granulomatous lessions
oculometry as an attentional mechanism evaluation tool and attention deficit hyperactivity inhibition

Conditions: Attention Deficit-Hyperactivity

Summary: the aim of this study is to analyse thanks to eye tracking experiments ocular movement classical parameters in children with attention deficit hyperactivity (adh) and to compare them to results obtained in healthy children and to results obtained with neuropsychological tests commonly used in standard health care. we should then be able to compare eye tracking with neuropsychological parameters. the final objective is to give to health professional a tool for adh investigation with which they should be able to do a simple and effective follow up of children with adh.


Eligibility criteria:
inclusion criteria: * children between 8 and 12 years old * boys and girls * dsm-iv-tr diagnostic criteria for adh * children with methylprednisone treatment * social security affiliation * signed informed consent exclusion criteria: * specialised scholarship * refusal from children or parents * too law results in wisc test (pre-inclusion test)
wecareadvisor study for caregivers of people living with dementia

Conditions: Dementia; Caregiver Burnout; Caregiver Stress Syndrome; Alzheimer Disease; Frontotemporal Dementia; Vascular Dementia; Dementia With Lewy Bodies

Summary: the wecareadvisor is an online tool to help caregivers manage behavioral and psychological symptoms of people living with dementia. the trial will evaluate its efficacy to reduce caregiver distress, improve confidence managing behaviors, as well as reduce occurrences and severity of behavioral and psychological symptoms. visit https://wecareadvisorstudy.com/ for more information.

caregivers enrolled in the study will use the web-based wecareadvisor tool for either three or six months, depending upon group allocation (immediate treatment vs. 3-month waitlist). caregivers will be interviewed at baseline, 1, 3 and 6 months by telephone to evaluate their health and wellbeing. also, utilization data of the tool will be captured.

Eligibility criteria:
inclusion criteria: * self-identify as the primary caregiver to the person living with memory loss or dementia; * has been a primary caregiver for at least 6 months; * report managing \>1 behavioral symptom(s) in the past month; * has an email account or smartphone (to receive daily tips and reminder messages); * english speaking; * has own smartphone, tablet, laptop, or desktop computer and access to internet; * if person living with dementia is on an anti-dementia or psychotropic medication, they must be on a stable dose for at least 60 days prior to enrollment. * if caregiver is on an anti-depression or other psychotropic medication, they must be on a stable does for at least 60 days prior to enrollment * lives in the united states or us territory exclusion criteria: * caregiver currently involved in another clinical trial of psychosocial or educational interventions for dementia; * caregiver has a visual impairment that prohibits interaction with the tool, and/or have a hearing impairment sufficient to prohibit telephone communication; * caregiver reports person living with dementia is not responsive to his/her environment (e.g., unable to understand short commands or recognize a person coming in/out of the room); * caregiver reports person living with dementia is an active suicide risk * caregiver reports person living with dementia is likely to have an imminent placement in a long-term care facility (within 6 months). * either caregiver/person living with dementia has a terminal disease with life expectancy \< 6 months, is in active treatment for cancer, or has had more than 3 acute medical hospitalizations over the past year.

Keywords: dementia caregiver alzheimer's disease memory loss
ultrasonographic parameters in stroke patients with dysphagia

Conditions: Stroke; Dysphagia

Summary: ultrasonographic parameters in stroke patients with dysphagia


Eligibility criteria:
inclusion criteria: diagnosis of stroke, * agreeing to participate in the study, * cognitive competence to understand the test instructions * communication skills to respond to the test instructions. exclusion criteria: * presence of a neurological disease other than stroke that will cause difficulty in swallowing, -being illiterate, * refusing to participate in the study, * jaw joint problem, * surgical intervention in the neck area that will affect ultrasound measurements, * infected open wound
a trial to evaluate the effect of applying leukapheresis to enrich ctcs in mpca patients

Conditions: Prostate Cancer; Circulating Tumor Cell; Leukapheresis

Summary: the goal of this observational study is to compare the number of ctcs enriched by both sampling methods, leukapheresis and collection of peripheral blood in metastatic prostate cancer patients. the main questions it aims to answer are: 1. the advantages and disadvantages of two sampling methods for further diagnosis and treatment; 2. how to obtain further information on the tumour biology of ctc; 3. the mechanisms of prostate cancer invasion and metastasis participants will have 7.5ml of peripheral blood taken as well as undergo leukapheresis.


Eligibility criteria:
inclusion criteria: 1. male, aged 18-75 years; and 2. evidence of metastasis (positive finding of metastasis on one of the following tests: ct and mri; whole-body nuclear bone imaging, fluoride pet and pet-ct, cholinergic pet-ct and mri; prostate-specific membrane antigen-targeted pet-ct); or clinical diagnosis of metastatic prostate cancer (tumour stage of t3 and above) by pathology of aspiration/surgical biopsy; 3. good general condition, ecog score 0-1, able to tolerate leukapheresis; 4. normal haematological analysis, liver and renal function tests at screening; 5. subjects (or their legal representatives) can understand the informed consent form. exclusion criteria: 1. those who have received systemic combination therapy for tumours within 5 years; 2. those with poor general condition, severe haemodynamic instability, malignant arrhythmias, cachexia and infections 3. those with coagulation disorders, dic or reduced platelets; 4. those receiving exogenous plasma at the time of the trial;
a study to learn more about how drug aflibercept works in canadian patients with reduced vision caused by new blood vessels growing in the eye (myopic choroidal neovascularization or mcnv)

Conditions: Myopic Choroidal Neovascularization

Summary: being short sighted means that vision is blurry when looking at things far away. people with a condition called "pathologic myopia" are short sighted due to problems in the back layer of their eyes, also known as the retina. some people with pathologic myopia can develop a serious condition called myopic choroidal neovascularization (mcnv). in people with mcnv, new blood vessels grow into the retina. these blood vessels can break, leaking blood or fluid into the retina. this can cause blurry vision or a loss of vision. in this study, researchers will find out more about how well drug aflibercept works and how safe it is in canadian patients with mcnv. the researchers in this study will review information from the patients' eye doctor visits. the patients in this study will include canadian men and women who started receiving aflibercept between may 2017 and august 2019. these patients were at least 18 years old and had not received treatment for their mcnv before. the researchers will look at the results of vision tests to find out how well the patients could read from a distance after they received aflibercept for 6 months. they will compare the results of these tests to before the patients received treatment. they will also learn more about how safe it is to have aflibercept injection into the eye.


Eligibility criteria:
inclusion criteria: * adult (age ≥ 18 years) female or male patient. * anti-vegf treatment naïve patients diagnosed with mcnv. * initiation of treatment with aflibercept was made as per investigator's routine treatment practice between 01 may 2017 and 31 aug 2019. exclusion criteria: * any participation in an investigational program with interventions outside of routine clinical practice. * patients who have previously been treated with anti-vegf intravitreal injections, systemic anti-vegf or pro-vegf treatments, as well as other intravitreal steroids or steroid implants for the study eye. * patients with another retinal disease (e.g. wet age-related macular degeneration,-wamd; diabetic macular edema-dme; retinal vein occlusion-rvo), patients with advanced cataracts or glaucoma, or patients with scarring, fibrosis, or atrophy involving the center of the fovea.

Keywords: intravitreal aflibercept choroidal neovascularization vascular endothelial growth factor (vegf)
sitagliptin metformin add-on study in patients with type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus (T2DM)

Summary: a clinical study to determine the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus who have inadequate glycemic (blood sugar) control on metformin therapy.


Eligibility criteria:
inclusion criteria: * patient has type 2 diabetes mellitus * males * females who are highly unlikely to become pregnant * patients poorly controlled while taking one or two oral antidiabetic medications exclusion criteria: * patient has a history of type 1 diabetes mellitus or history of ketoacidosis * patient required insulin therapy within the prior 8 weeks * patient is on or has been taking thiazolidinediones (tzds) such as actos® (pioglitazone) or avandia® (rosiglitazone) or is on or has been taking byetta® (exenatide) within the prior 12 weeks of the screening visit
community colorectal cancer awareness, research, education & screening (c-cares)

Conditions: Colorectal Cancer

Summary: the purpose of this study is to test if including personalization in education materials about colorectal cancer screening is more effective at helping encourage people to complete colorectal cancer screening.


Eligibility criteria:
inclusion criteria: * able to understand, read and speak english or spanish * are not up-to-date with colorectal cancer screening * no symptoms of colorectal cancer * not at increased risk for colorectal cancer due to family history or personal high-risk gi syndromes exclusion criteria: * symptoms of colorectal cancer * family history of colorectal cancer

Keywords: colorectal cancer screening fit test fecal immunochemical test